Comparison of LAMA/LABA inhalers (update February 2021)
Comparison tables are produced for prescribers and medicines management teams. They are designed to assist in prescribing and decision-making within a specific therapeutic area.
Long-acting muscarinic antagonists (LAMAs) and long-acting beta2 agonists (LABAs) are available in a variety of combination inhaler devices. This comparison table allows prescribers and other healthcare professionals to easily compare the characteristics of these medicines.
For information on the carbon impact of inhalers, see our Prescribing for Population Health publications.
Oral Vitamin B supplementation
This document aims to support the Regional Medicines Optimisation Committees (RMOC) position statement; “Oral vitamin B supplementation in alcoholism” by identifying CCGs and geographical areas where prescribing within primary care may not be in line with the recommendations.
There is ongoing prescribing of vitamin B complex products despite national and local recommendations that this should be reserved for supplementation in the context of refeeding syndrome. Medicines optimisation teams should be advised to review the formulary status of vitamin B compound products and implement a deprescribing programme if necessary.
This review is older than 18 months; in view of the continued emergence of new evidence, readers are recommended to re-check the biomedical literature.
There are three versions of this publication; please select the appropriate version for your region below.
Comparison of SGLT2 inhibitors (update)
Comparison tables are produced for prescribers and medicines management teams. They are designed to assist in prescribing and decision-making within a specific therapeutic area.
Several sodium-glucose co-transporter 2 inhibitors are marketed. This comparison table allows prescribers and other healthcare professionals to easily compare the characteristics of these medicines.
Levodopa inhalation powder for episodic motor fluctuations in Parkinson’s disease
Overview
New Drug Evaluations are concise, structured reviews of new drugs recently launched within the NHS. These documents seek to provide a brief overview of the efficacy, safety and cost of new drugs.
Inbrija®▼ (Acorda Therapeutics), a levodopa powder for oral inhalation, is licensed for the intermittent treatment of episodic motor fluctuations (OFF episodes) in adult patients with Parkinson’s disease (PD) treated with a levodopa/dopa-decarboxylase inhibitor.
This review is older than 18 months; in view of the continued emergence of new evidence, readers are recommended to re-check the biomedical literature.
Download the full review below to read more.
NICE has accredited the process used by the Regional Drug and Therapeutics Centre to produce New Drug Evaluations. Accreditation is valid until the 31st of December 2023.
For more information visit www.nice.org/accreditation